New search

Page 1 15:18 Print selected from Onli 07/23/2003

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1626gms

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY
NEWS 28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:15:12 ON 23 JUL 2003

=> FIL CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 15:15:16 ON 23 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Jul 2003 VOL 139 ISS 4
FILE LAST UPDATED: 22 Jul 2003 (20030722/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s displacement(w)chromatography?
         89208 DISPLACEMENT
         16977 DISPLACEMENTS
        101646 DISPLACEMENT
                (DISPLACEMENT OR DISPLACEMENTS)
        285871 CHROMATOGRAPHY?
        549282 CHROMATOG
          3045 CHROMATOGS
        551491 CHROMATOG
                (CHROMATOG OR CHROMATOGS)
        643047 CHROMATOGRAPHY?
                (CHROMATOGRAPHY? OR CHROMATOG)
L1         618 DISPLACEMENT(W)CHROMATOGRAPHY?

=> s l1 and reductase
         72580 REDUCTASE
          5846 REDUCTASES
         73531 REDUCTASE
                (REDUCTASE OR REDUCTASES)
L2           2 L1 AND REDUCTASE

=> s l1 and HMG?
          9072 HMG?
L3           2 L1 AND HMG?
```

```
=> S L1 and COA(W)reductase
         35852 COA
           827 COAS
         36018 COA
                 (COA OR COAS)
         72580 REDUCTASE
          5846 REDUCTASES
         73531 REDUCTASE
                 (REDUCTASE OR REDUCTASES)
          7819 COA(W)REDUCTASE
L4           2 L1 AND COA(W)REDUCTASE

=> d l2 ibib abs hitstr tot

L2   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2001:334067  CAPLUS
DOCUMENT NUMBER:          135:225890
TITLE:                    Chromatographic purification of some
                          3-hydroxy-3-methylglutaryl coenzyme A
                          reductase inhibitors
AUTHOR(S):                Grahek, R.; Milivojevic, D.; Bastarda, A.; Kracun, M.
CORPORATE SOURCE:         Lek d.d., Research and Development, Ljubljana, 1526,
                          Slovenia
SOURCE:                   Journal of Chromatography, A (2001), 918(2), 319-324
                          CODEN: JCRAEY; ISSN: 0021-9673
PUBLISHER:                Elsevier Science B.V.
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   The purifn. of pravastatin, simvastatin and lovastatin in the sodium salt
     or lactone form and of mevastatin in the lactone form by reversed-phase
     displacement chromatog. is presented. The mobile phases
     consisted of water or mixts. of water-methanol and water-acetonitrile.
     Six different displacers were successfully used. Up to 0.14 g of raw
     sample per g of stationary phase was loaded on a column packed with
     silica-based octadecyl phase. Crude substances from 85 to 88% chromatog.
     purity were purified and at least 99.5% purity was achieved.
REFERENCE COUNT:          28    THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2000:210141  CAPLUS
DOCUMENT NUMBER:          132:241979
TITLE:                    Process for obtaining HMG-CoA reductase
                          inhibitors of high purity
INVENTOR(S):              Grahek, Rok; Milivojevic, Dusan; Bastarda, Andrej
PATENT ASSIGNEE(S):       Lek Pharmaceutical and Chemical Company D.D., Slovenia
SOURCE:                   PCT Int. Appl., 25 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ----------------  ----  --------      ---------------  --------
     WO 2000017182      A1   20000330      WO 1999-IB1553   19990917
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
             KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
             MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
             TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
```

MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

SI 20072	C	20000430	SI 1998-241	19980918
CA 2343645	AA	20000330	CA 1999-2343645	19990917
AU 9955284	A1	20000410	AU 1999-55284	19990917
EP 1114040	A1	20010711	EP 1999-941797	19990917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526486	T2	20020820	JP 2000-574092	19990917
HR 2001000045	A1	20011231	HR 2001-45	20010116
BG 105348	A	20011130	BG 2001-105348	20010316

PRIORITY APPLN. INFO.: SI 1998-241 A 19980918
WO 1999-IB1553 W 19990917

AB Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivs. and analogs are known as HMG-CoA **reductase** inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermn. using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermn. products using the method of chem. synthesis or they are the products of total chem. synthesis. The purity of the active ingredient is an important factor for manufg. the safe and effective pharmaceutical, esp. if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment. The present invention relates to a new industrial process for the isolation of HMG-CoA **reductase** inhibitors using so-called **displacement chromatog.** Use of the invention enables to obtain HMG-CoA **reductase** inhibitors of high purity, with high yields, lower prodn. costs and suitable ecol. balance. Crude sodium salt of pravastatin (HPLC purity 88%) was dissolved in the mobile phase A (distd. water), pH was adjusted to 7 with 0.2M aq. NaOH soln. and filtered. The column was equilibrated with mobile phase A. The sample obtained in the above manner was fed onto the Grom-Sil 120-ODS HE column (particle size 30 11 .mu.m, column size 250 x 10 mm). The column was washed with the mobile phase B contg. 7% of diethylene glycol monobutyl ether in mobile phase A at the flow rate of 4.5 mL/min. Absorbance was measured at 260 nm, and the 0.5 mL fractions were collected with an initial increase in the absorbance. When the signal decreased the column was washed with 25 mL of 70% MeOH. The fractions obtained were analyzed by the HPLC method. The fractions with a purity 99.5% were pooled. In the pooled fractions (7 mL), the HPLC purity was 99.8%.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l3 ibib abs hitstr tot

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:210141 CAPLUS
DOCUMENT NUMBER: 132:241979
TITLE: Process for obtaining **HMG**-CoA reductase inhibitors of high purity
INVENTOR(S): Grahek, Rok; Milivojevic, Dusan; Bastarda, Andrej
PATENT ASSIGNEE(S): Lek Pharmaceutical and Chemical Company D.D., Slovenia
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017182	A1	20000330	WO 1999-IB1553	19990917
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
SI 20072	C	20000430	SI 1998-241	19980918
CA 2343645	AA	20000330	CA 1999-2343645	19990917
AU 9955284	A1	20000410	AU 1999-55284	19990917
EP 1114040	A1	20010711	EP 1999-941797	19990917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526486	T2	20020820	JP 2000-574092	19990917
HR 2001000045	A1	20011231	HR 2001-45	20010116
BG 105348	A	20011130	BG 2001-105348	20010316

PRIORITY APPLN. INFO.: SI 1998-241 A 19980918
WO 1999-IB1553 W 19990917

AB Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivs. and analogs are known as **HMG**-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermn. using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermn. products using the method of chem. synthesis or they are the products of total chem. synthesis. The purity of the active ingredient is an important factor for manufg. the safe and effective pharmaceutical, esp. if the pharmaceutical product must be taken on a longer term basis in the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment. The present invention relates to a new industrial process for the isolation of **HMG**-CoA reductase inhibitors using so-called **displacement chromatog**. Use of the invention enables to obtain **HMG**-CoA reductase inhibitors of high purity, with high yields, lower prodn. costs and suitable ecol. balance. Crude sodium salt of pravastatin (HPLC purity 88%) was dissolved in the mobile phase A (distd. water), pH was adjusted to 7 with 0.2M aq. NaOH soln. and filtered. The column was equilibrated with mobile phase A. The sample obtained in the above manner was fed onto the Grom-Sil 120-ODS HE column (particle size 30 11 .mu.m, column size 250 x 10 mm). The column was washed with the mobile phase B contg. 7% of diethylene glycol monobutyl ether in mobile phase A at the flow rate of 4.5 mL/min. Absorbance was measured at 260 nm, and the 0.5 mL fractions were collected with an initial increase in the absorbance. When the signal decreased the column was washed with 25 mL of 70% MeOH. The fractions obtained were analyzed by the HPLC method. The fractions with a purity 99.5% were pooled. In the pooled fractions (7 mL), the HPLC purity was 99.8%.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1982:449945 CAPLUS
DOCUMENT NUMBER: 97:49945

TITLE: Identification of protein(s) secreted by the preovulatory ovary which suppresses the follicle response to gonadotropins
AUTHOR(S): DiZerega, Gere S.; Goebelsmann, Uwe; Nakamura, Robert M.
CORPORATE SOURCE: Sch. Med., Univ. Southern California, Los Angeles, CA, 90033, USA
SOURCE: Journal of Clinical Endocrinology and Metabolism (1982), 54(6), 1091-6
CODEN: JCEMAZ; ISSN: 0021-972X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Ovarian venous blood (5 mL) was collected from women undergoing laparotomy for indications not related to ovarian dysfunction on days 12-14 after the onset of their last menstrual period. Serum was fractionated by (NH4)2SO4 pptn., dialyzed against buffer with 10,000 mol. wt. exclusion membranes, and thereafter sequentially eluted through concanavalin A and Sephadex G-50 columns. The activity of the eluent was assessed as inhibition of ovarian wt. increase and serum 17.beta.-estradiol [50-28-2] levels in 23-day-old, hypophysectomized, diethylstilbestrol-treated rats (HIFR) challenged with human menopausal gonadotropin (**hMG**) [61489-71-2]. Sephadex G-50 fractions (elution vol./void vol. 1.42-1.55) from patient 1 produced a decrease in ovarian wt. (59 vs. 89.1 g) and a decrease in serum 17.beta.-estradiol levels (<25 vs. 215.5 pg/mL). Although peripheral and ovarian venous blood collected from the ovary contralateral to the site of ovulation demonstrated similar Sephadex G-50 elution profiles, when representative fractions were tested by bioassay, no redn. in ovarian wt. or serum 17.beta.-estradiol levels was found. In addn., ovarian venous serum from the ovulatory ovary of patients 2 and 3 had a similar Sephadex G-50 elution profile with fractions (elution vol./void vol. = 1.48-1.60) which suppressed rat ovarian wt. and serum 17.beta.-estradiol concns. in the **hMG**-HIFR assay. When active fractions from the G-50 eluents were heated to 56.degree. or trypsin digested, they lost their ability to suppress ovarian wt. and 17.beta.-estradiol secretion in response to **hMG** stimulation. Estns. of mol. wt. by gel permeation ranged 14,000-18,000 for patients 1-3. Bioassay results from representative fractions obtained by ampholyte **displacement chromatog**. suggested that the isoelec. point of active material was pH, 5.8-6.5 for patients 1-3. Similarly processed samples from 3 anovulatory patients contained no inhibitory activity in the bioassay. Thus, the identification of a heat- and trypsin-labile substance secreted directly into the venous drainage from the ovary contg. the dominant follicle which suppresses the follicular response to gonadotropins is reported. That this protein is not secreted in large amts. by anovulatory ovaries was evidenced by the failure of the bioassay to detect inhibitory activity in the venous drainage of the contralateral ovary of patients 1-3 as well as the ovarian venous effluents from 3 anovulatory women.

=> d l4 ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:334067 CAPLUS
DOCUMENT NUMBER: 135:225890
TITLE: Chromatographic purification of some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
AUTHOR(S): Grahek, R.; Milivojevic, D.; Bastarda, A.; Kracun, M.
CORPORATE SOURCE: Lek d.d., Research and Development, Ljubljana, 1526, Slovenia
SOURCE: Journal of Chromatography, A (2001), 918(2), 319-324

CODEN: JCRAEY; ISSN: 0021-9673
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The purifn. of pravastatin, simvastatin and lovastatin in the sodium salt or lactone form and of mevastatin in the lactone form by reversed-phase **displacement chromatog.** is presented. The mobile phases consisted of water or mixts. of water-methanol and water-acetonitrile. Six different displacers were successfully used. Up to 0.14 g of raw sample per g of stationary phase was loaded on a column packed with silica-based octadecyl phase. Crude substances from 85 to 88% chromatog. purity were purified and at least 99.5% purity was achieved.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:210141 CAPLUS
DOCUMENT NUMBER: 132:241979
TITLE: Process for obtaining HMG-**CoA reductase** inhibitors of high purity
INVENTOR(S): Grahek, Rok; Milivojevic, Dusan; Bastarda, Andrej
PATENT ASSIGNEE(S): Lek Pharmaceutical and Chemical Company D.D., Slovenia
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017182	A1	20000330	WO 1999-IB1553	19990917
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
SI 20072	C	20000430	SI 1998-241	19980918
CA 2343645	AA	20000330	CA 1999-2343645	19990917
AU 9955284	A1	20000410	AU 1999-55284	19990917
EP 1114040	A1	20010711	EP 1999-941797	19990917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526486	T2	20020820	JP 2000-574092	19990917
HR 2001000045	A1	20011231	HR 2001-45	20010116
BG 105348	A	20011130	BG 2001-105348	20010316

PRIORITY APPLN. INFO.: SI 1998-241 A 19980918
WO 1999-IB1553 W 19990917

AB Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivs. and analogs are known as HMG-**CoA reductase** inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermn. using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, some are obtained by treating the fermn. products using the method of chem. synthesis or they are the products of total chem. synthesis. The purity of the active ingredient is an important factor for manufg. the safe and effective pharmaceutical, esp. if the pharmaceutical product must be taken on a longer term basis in

the treatment or prevention of high plasma cholesterol. The accumulation of the impurities from the pharmaceuticals of lower purity may cause many side effects during the medical treatment. The present invention relates to a new industrial process for the isolation of HMG-**CoA reductase** inhibitors using so-called **displacement chromatog**. Use of the invention enables to obtain HMG-**CoA reductase** inhibitors of high purity, with high yields, lower prodn. costs and suitable ecol. balance. Crude sodium salt of pravastatin (HPLC purity 88%) was dissolved in the mobile phase A (distd. water), pH was adjusted to 7 with 0.2M aq. NaOH soln. and filtered. The column was equilibrated with mobile phase A. The sample obtained in the above manner was fed onto the Grom-Sil 120-ODS HE column (particle size 30 11 .mu.m, column size 250 x 10 mm). The column was washed with the mobile phase B contg. 7% of diethylene glycol monobutyl ether in mobile phase A at the flow rate of 4.5 mL/min. Absorbance was measured at 260 nm, and the 0.5 mL fractions were collected with an initial increase in the absorbance. When the signal decreased the column was washed with 25 mL of 70% MeOH. The fractions obtained were analyzed by the HPLC method. The fractions with a purity 99.5% were pooled. In the pooled fractions (7 mL), the HPLC purity was 99.8%.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT